Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer

• Yali Yi,
• Jing Cai,
• Peng Xu,
• Le Xiong,
• Zhiqin Lu,
• Zhimin Zeng,
• Anwen Liu

Affiliations

Yali Yi

Department of Oncology, The Second Affiliated Hospital of Nanchang University

Jing Cai

Department of Oncology, The Second Affiliated Hospital of Nanchang University

Peng Xu

Department of Oncology, The Second Affiliated Hospital of Nanchang University

Le Xiong

Department of Oncology, The Second Affiliated Hospital of Nanchang University

Zhiqin Lu

Department of Oncology, The Second Affiliated Hospital of Nanchang University

Zhimin Zeng

Department of Oncology, The Second Affiliated Hospital of Nanchang University

Anwen Liu

Department of Oncology, The Second Affiliated Hospital of Nanchang University